Long-term follow-up of psilocybin-facilitated smoking cessation

References

• World Health Organization. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. Geneva: World Health Organization; 2011.
   Google Scholar
• Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311:193–194. doi:10.1001/jama.2013.283787.
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O’Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M. Behavioural interventions for smoking cessation: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:718–730. doi:10.1093/eurheartj/ehn552.
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 2014;28(11):983–992. doi: 10.1177/0269881114548296.
   PubMed Web of Science ®Google Scholar
• Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J, eds. Measuring alcohol consumption. Rockville, MD: Humana Press; 1992:207–224. doi:10.1007/978-1-4612-0357-5_3.
   Google Scholar
• Griffiths R, Richards W, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 2006;187(3):268–283. doi:10.1007/s00213-006-0457-5.
   PubMed Web of Science ®Google Scholar
• Griffiths, RR, Richards WA, Johnson MW, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 2008;22(6):621–632. doi: 10.1177/0269881108094300.
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology (Berl). 2011;218(4):649–665. doi: 10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• MacLean KA, Leoutsakos JMS, Johnson MW, Griffiths RR. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 2012;51:721–737. doi:10.1111/j.1468-5906.2012.01685.x.
   PubMed Web of Science ®Google Scholar
• Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol 2015;29:1182–1190. doi:10.1177/0269881115609019.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Griffiths R, Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2014;7(3):157–164. doi: 10.2174/1874473708666150107121331.
   PubMedGoogle Scholar
• Javors MA, Hatch JP, Lamb RJ. Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 2005;100:159–167. doi:10.1111/j.1360-0443.2004.00957.x.
   PubMed Web of Science ®Google Scholar
• Bramer S, Kallungal B. Clinical considerations in study designs that use cotinine as a biomarker. Biomarkers 2003;8:187–203. doi:10.1080/13547500310012545.
   PubMed Web of Science ®Google Scholar
• Dallal GE, Wilkinson L. An analytic approximation to the distribution of Lilliefors’s test statistic for normality. Am Stat 1986;40:294–296.
   Web of Science ®Google Scholar
• Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. Am J Med 2008;121:S32–S42. doi:10.1016/j.amjmed.2008.01.017.
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Tonstad S, Hjalmarson A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 2003;254:184–192. doi:10.1046/j.1365-2796.2003.01185.x.
   PubMed Web of Science ®Google Scholar
• Coyle C, Crum RM, Ford DE. Associations between spirituality and substance abuse symptoms in the Baltimore Epidemiologic Catchment Area follow-up, 1993–1996. J Addict Dis 2006;25:125–132. doi:10.1300/J069v25n04_12.
   PubMed Web of Science ®Google Scholar
• Piderman KM, Schneekloth TD, Pankratz VS, et al. Spirituality in alcoholics during treatment. Am J Addict 2007;16:232–237. doi:10.1080/10550490701375616.
   PubMed Web of Science ®Google Scholar
• Piedmont RL. Spiritual transcendence as a predictor of psychosocial outcome from an outpatient substance abuse program. Psychol Addict Behav 2004;18:213–222. doi:10.1037/0893-164x.18.3.213.
   PubMed Web of Science ®Google Scholar
• Zemore SE. A role for spiritual change in the benefits of 12‐step involvement. Alcohol Clin Exp Res 2007;31(s3):76s–79s. doi:10.1111/j.1530-0277.2007.00499.x.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Redtomahawk D, Pizacani B, et al. Support for spirituality in smoking cessation: results of pilot survey. Nicotine Tob Res 2007;9:299–303. doi:10.1080/14622200601078582.
   PubMed Web of Science ®Google Scholar
• MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 2011;25:1453–1461. doi:10.1177/0269881111420188.
   PubMed Web of Science ®Google Scholar
• Krebs TS, Johansen PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012;26:994–1002. doi: 10.1177/0269881112439253.
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PCR, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29:289–299. doi:10.1177/0269881114565144.
   PubMed Web of Science ®Google Scholar